(1991). A controlled cortical impact model of traumatic brain injury in the rat.
(1996). A molecular mechanism for the effect of lithium on development.
(1997). Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury.
(1996). Apoptotic morphology of dentate gyrus granule cells following experimental cortical impact injury in rats: possible role in spatial memory deficits.
(2005). Bench-tobedside review: Apoptosis/programmed cell death triggered by traumatic brain injury.
(2000). Biochemical, cellular, and molecular mechanisms in the evolution of secondary damage after severe traumatic brain injury in infants and children: Lessons learned from the bedside. Pediatr Crit Care Med
(2000). Caspase-3 mediated neuronal death after traumatic brain injury in rats.
(2001). Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain.
(2003). Chronic treatment with lithium, but not sodium valproate, increases cortical Nacetyl-aspartate concentrations in euthymic bipolar patients.
(1999). Cloning and characterization of a mammalian lithium-sensitive bisphosphate 39-nucleotidase inhibited by inositol 1,4-bisphosphate.
(1992). Cognitive deficits following traumatic brain injury produced by controlled cortical impact.
(2009). Combination therapies for traumatic brain injury: prospective considerations.
(2008). Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model.
(1996). Delayed, selective neuronal death following experimental cortical impact injury in rats: possible role in memory deficits.
(2008). Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/betaCatenin signaling.
(2002). Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage.
(2010). Emerging links between CDK cell cycle regulators and Wnt signaling.
(2010). Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain.
(1999). Exacerbation of damage and altered NF-kappaB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury.
(2007). Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium.
(2004). Glycogen synthase kinase-3 inhibitors prevent caspase-dependent apoptosis induced by ethanol in cultured rat cortical neurons.
(2003). Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity.
(2003). GSK-3: tricks of the trade for a multi-tasking kinase.
(2009). GSK3 inhibitors show benefits in an Alzheimer’s disease (AD) model of neurodegeneration but adverse effects in control animals.
(1993). Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growthfactor signalling.
(2006). Increased phosphorylation of protein kinase B and related substrates after traumatic brain injury in humans and rats.
(1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.
(2010). Inhibition of GSK3 attenuates dopamine D1 receptor agonist-induced hyperactivity in mice.
(2009). Inhibition of GSK3 phosphorylation of beta-Catenin via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6. PLoS
(2003). Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3.
(2005). Lateral fluid percussion brain injury: a 15-year review and evaluation.
(1999). Lithium activates the serine/ threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons.
(2009). Lithium attenuates behavioral and biochemical effects of neuropeptide S in mice.
(2000). Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects?
(2011). Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study.
(2001). Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K+ deprivation in cerebellar granule cells.
(1996). Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells.
(2002). Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation.
(2000). Lithium-induced increase in human brain grey matter.
(2009). Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety.
(1992). Measurement of lithiuminduced changes in mouse inositol(1)phosphate levels in vivo.
(1995). Molecular biology of CNS injury.
(2001). Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders.
(2002). Neuroprotection and traumatic brain injury: theoretical option or realistic proposition.
(2010). Neuroprotective effect and cognitive outcome of chronic lithium on traumatic brain injury in mice.
(2007). Neurotrophin-mediated neuroprotection of hippocampal neurons following traumatic brain injury is not associated with acute recovery of hippocampal function.
(2004). NMDA receptor 2B-selective antagonist ifenprodil-induced apoptosis was prevented by glycogen synthase kinase-3 inhibitors in cultured rat cortical neurons.
(1999). One-year study of spatial memory performance, brain morphology, and cholinergic markers after moderate controlled cortical impact in rats.
(2006). P2 purinergic receptors signal to glycogen synthase kinase-3beta in astrocytes.
(2009). Persistent working memory dysfunction following traumatic brain injury: Evidence for a time-dependent mechanism.
(2000). Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci
(2006). Polytherapy in bipolar disorder.
(2003). Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model.
(1998). Potential contribution of proteases to neuronal damage.
(2003). Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3.
(2010). Regulation of Lrp6 phosphorylation.
(2007). Role of glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic brain injury.
(2000). Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.
(1995). Spatial memory deficits, increased phosphorylation of the transcription factor CREB, and induction of the AP-1 complex following experimental brain injury.
(2008). Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition.
(2004). The glamour and gloom of glycogen synthase kinase-3.
(2008). The life of a cell: apoptosis regulation by the PI3K/PKB pathway.
(2001). The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth.
(2001). The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling.
(2006). The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways.
(1978). The pharmacokinetics of lithium in the brain, cerebrospinal fluid and serum of the rat.
(2002). The role of extracellular signal-regulated kinase in cognitive and motor deficits following experimental traumatic brain injury.
(2010). Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats.